1.82
-0.05(-2.67%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.9 |
| Day High | 1.94 |
| Day Low | 1.81 |
| 52-Week High | 2.71 |
| 52-Week Low | 0.69 |
| Volume | 79,091 |
| Average Volume | 2.25M |
| Market Cap | 87.18M |
| PE | -1.48 |
| EPS | -1.23 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 1.2 |
| Change | -0.05 |
If you invested $1000 in Shattuck Labs, Inc. (STTK) since IPO date, it would be worth $94.06 as of October 15, 2025 at a share price of $1.82. Whereas If you bought $1000 worth of Shattuck Labs, Inc. (STTK) shares 3 years ago, it would be worth $594.77 as of October 15, 2025 at a share price of $1.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
GlobeNewswire Inc.
Oct 02, 2025 11:51 AM GMT
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
GlobeNewswire Inc.
Aug 26, 2025 10:30 AM GMT
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assumi
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
GlobeNewswire Inc.
Aug 21, 2025 2:17 PM GMT
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in it